Okutani R, Philbin D M, Rosow C E, Koski G, Schneider R C
Henry K. Beecher Memorial Research Laboratories, Department of Anesthesia, Harvard Medical School, Massachusetts General Hospital, Boston 02114.
Anesth Analg. 1988 Jul;67(7):667-70.
The effect of hypothermic hemodilutional cardiopulmonary bypass (CPB) on plasma sufentanil and catecholamine concentrations was studied in four groups of ten patients each, receiving four different doses of sufentanil. Samples for measurement of sufentanil were obtained before CPB, at 15, 30, and 45 minutes of CPB, during rewarming, immediately after and 15, 60, and 240 minutes after CPB. In addition, in groups III and IV, which received the highest dose of sufentanil, blood samples were also obtained for measurement of plasma levels of epinephrine and norepinephrine. Sufentanil concentration decreased in all groups with the start of CPB (group I, 2.92 +/- 0.2 to 2.04 +/- 0.2; group II, 3.30 +/- 0.3 to 1.51 +/- 0.2; group III, 7.08 +/- 0.7 to 3.45 +/- 0.3; group IV, 10.33 +/- 0.5 to 4.59 +/- 0.5 ng/ml). No further decreases occurred during CPB but increases occurred with rewarming. The first measurement after CPB approached the concentration before CPB (group I, 2.82 +/- 0.3; group II, 2.56 +/- 0.5; group III, 4.42 +/- 0.4; group IV, 6.10 +/- 0.4 ng/ml). Norepinephrine concentrations demonstrated a wide variability with no significant changes. Epinephrine levels increased significantly during rewarming in both groups (group III, 141 +/- 23 to 279 +/- 79 pg/ml; P less than 0.05; group IV, 105 +/- 24 to 267 +/- 68 pg/ml, P less than 0.05). The stability of plasma sufentanil concentrations during CPB suggest that no measurable metabolism or excretion occurred. The increase with rewarming and after CPB suggest significant sequestration.(ABSTRACT TRUNCATED AT 250 WORDS)
在四组患者(每组10例)中研究了低温血液稀释体外循环(CPB)对血浆舒芬太尼和儿茶酚胺浓度的影响,这四组患者接受了四种不同剂量的舒芬太尼。在CPB前、CPB进行15、30和45分钟时、复温期间、CPB结束后即刻以及CPB结束后15、60和240分钟采集用于测定舒芬太尼的样本。此外,在接受最高剂量舒芬太尼的III组和IV组中,还采集血样用于测定血浆肾上腺素和去甲肾上腺素水平。随着CPB开始,所有组的舒芬太尼浓度均下降(I组,从2.92±0.2降至2.04±0.2;II组,从3.30±0.3降至1.51±0.2;III组,从7.08±0.7降至3.45±0.3;IV组,从10.33±0.5降至4.59±0.5 ng/ml)。CPB期间未进一步下降,但复温时浓度升高。CPB后首次测量的浓度接近CPB前的浓度(I组,2.82±0.3;II组,2.56±0.5;III组,4.42±0.4;IV组,6.10±0.4 ng/ml)。去甲肾上腺素浓度变化较大,无显著变化。两组在复温期间肾上腺素水平均显著升高(III组,从141±23升至279±79 pg/ml;P<0.05;IV组,从105±24升至267±68 pg/ml,P<0.05)。CPB期间血浆舒芬太尼浓度的稳定性表明未发生可测量的代谢或排泄。复温和CPB后浓度升高表明有显著的潴留。(摘要截短于250字)